Epilepsy Pipeline and Clinical Trial Analysis Report | 70+ Companies and 70+ Drugs

DelveInsight's, "Epilepsy Pipeline Insight, 2023" report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape. It covers the Epilepsy pipeline drug profiles, including Epilepsy clinical trial and nonclinical stage products. It also covers the Epilepsy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Epilepsy pipeline products in this space.

In the Epilepsy Pipeline Report, detailed description of the drug is given which includes Epilepsy mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Epilepsy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the Epilepsy Pipeline Report

• DelveInsight's Epilepsy Pipeline analysis depicts the space with 70+ active players working to develop 70+ pipeline therapies.

• The leading Epilepsy Companies are developing potential drug candidates to improve the Epilepsy treatment scenario include Eisai Co.LTD, Alexza Pharmaceuticals, Xenon Pharmaceuticals, G W Pharmaceuticals, Equilibre Biopharmaceuticals, Takeda Pharmaceuticals, Abide therapeutics, Otsuka pharmaceutical, and others.

• Promising Epilepsy Pipeline Therapies are various stages of development include OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others.

• The Epilepsy Companies and academics are working to assess challenges and seek opportunities that could influence Epilepsy R&D. The Epilepsy pipeline therapies under development are focused on novel approaches to treat/improve Epilepsy.

Explore more information of the latest breakthroughs in the Epilepsy treatment landscape of the report, visit Epilepsy Pipeline Outlook @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Breakthroughs of the Epilepsy Treatment Landscape

• In January 2021, Addex Therapeutics announced that its partner Janssen Pharmaceuticals had received FDA's Investigational New Drug (IND) approval to begin a Phase IIa proof of concept study with the selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM), JNJ-40411813 (ADX71149), in patients with Epilepsy.

• In October 2020, PTC Therapeutics announced the initiation of a registration-directed Phase II/III clinical trial to evaluate vatiquinone (PTC743) in patients with mitochondrial Epilepsy, the highly morbid condition of refractory seizures in children with inherited mitochondrial disease.

Epilepsy Overview
Epilepsy is a chronic disorder that causes unprovoked, recurrent seizures. A seizure is a sudden rush of electrical activity in the brain. There are two main types of seizures. Generalized seizures affect the whole brain. Focal, or partial seizures, affect just one part of the brain. A mild seizure may be difficult to recognize. It can last a few seconds during which you lack awareness. Stronger seizures can cause spasms and uncontrollable muscle twitches, and can last a few seconds to several minutes. During a stronger seizure, some people become confused or lose consciousness. Afterward you may have no memory of it happening. Epilepsy is a fairly common neurological disorder that affects people around the world. In the United States, it affects about 3 million people.

Request a sample and discover the recent advances in Epilepsy Pipeline Therapies, visit Epilepsy Treatment Landscape @ https://www.delveinsight.com/sample-request/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Epilepsy Emerging Drugs

XEN1101: Xenon Pharmaceuticals
Xenon 1101, a differentiated KV7 potassium channel opener, for treatment of epilepsy. The Kv7 potassium channel mechanism has been clinically validated with ezogabine, an earlier generation Kv7 opener that was approved by the FDA as an adjunctive treatment for adults with focal seizures with or without secondary generalization. XEN1101's unique composition is chemically designed to improve upon potency, selectivity and pharmacokinetics, or PK, of ezogabine, and is not expected to have ezogabine's composition-specific tissue pigmentation effects. XEN1101 is a novel, small molecule, selective KCNQ2/3 (KV7.2/7.3) potassium channel positive allosteric modulator being developed for the treatment of partial onset (focal) epilepsy. Enhancing the open state of KCNQ2/3 in neurons favors a hyperpolarized resting state, which reduces rapid action potential spiking. This mechanism has been clinically proven to be effective for treatment of partial onset seizures in adults with epilepsy with the KCNQ2/3 opener, retigabine.

Lu AG06466: Abide therapeutics
Lu AG06466 (formerly ABX 1431) is an oral, small molecule, being developed by Abide Therapeutics (now Lundbeck A/S), for the treatment of neuropathic pain, Epilepsy. Currently, the drug is in Phase I stage of development for the treatment of Epilepsy.

TAK-935: Takeda Pharmaceuticals
Soticlestat is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor and modulates glutamatergic signaling associated with epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve excitatory/inhibitory balance of NMDA channel activity.

DelveInsight's Epilepsy Pipeline Report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Epilepsy Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Epilepsy Route of Administration

Epilepsy Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Epilepsy. The companies which have their Epilepsy drug candidates in the most advanced stage, i.e. phase II include, Xenon Pharmaceuticals.

For further information, refer to the detailed Epilepsy pipeline report, visit Epilepsy Emerging Drugs & Companies @ https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Epilepsy Pipeline Report
• Coverage: Global
• Epilepsy Companies: Otsuka Pharmaceutical Co. Ltd, Cerebral Therapeutics LLC, Marinus Pharmaceuticals, Xenon Pharmaceuticals, PTC Therapeutics, Eisai, Longboard Pharmaceuticals, Neurocrine Biosciences, and others.
• Key Epilepsy Pipeline Therapies: OPC-214870, CT-010, Ganaxolone, XEN496, Vatiquinone E-2730, LP352, NBI 827104, and others.
• Epilepsy Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration, Phases

Table of Content
1. Introduction
2. Executive Summary
3. Epilepsy Overview
4. Epilepsy Pipeline Therapeutics
5. Epilepsy Therapeutic Assessment
6. Epilepsy- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. Drug name : Company name
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. Drug name : Company name
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. XEN1101:Xenon Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Epilepsy Key Companies
21. Epilepsy Key Products
22. Epilepsy - Unmet Needs
23. Epilepsy - Market Drivers and Barriers
24. Epilepsy - Future Perspectives and Conclusion
25. Epilepsy Analyst Views
26. Epilepsy Key Companies
27. Appendix

Dive deep into rich insights for drugs for Epilepsy treatment, visit Epilepsy Market Drivers and Barriers @ https://www.delveinsight.com/report-store/epilepsy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.